Making sense of the Asembia 2025 Agenda using AI

1. Advanced & Emerging Therapies

Clinical innovation in specialty care: cell & gene, orphan/rare, next-generation biologics, GLP-1s and more.

• CE: Advancing Cystic Fibrosis Management: The Evolving Role of Specialty & Managed-Care Pharmacists

• CE: Emerging Treatment Options for Inflammatory Bowel Disease: Focus on IL-23 Pathway Inhibition

• CE: Pulmonary Arterial Hypertension: Real-World Applications of New Therapies & Management Strategies

• CE: Targeting Chronic Rhinosinusitis with Nasal Polyps with Biologics: Optimizing Outcomes & Reducing Burden

• CE: Reflecting on the Real-World Use of Biologic Therapy in Asthma Management

• CE: The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies & Strategies

• CE: Advancing Care in Neovascular AMD & Diabetic Macular Edema: Optimizing Outcomes with Emerging Therapies

• CE: Transforming MASLD (Steatohepatitis) Management: Pharmacist Considerations for an Evolving Landscape*

• CE: Leveraging Biologics & Immunotherapies in the Management of Food Allergies

• CE: Best Practices for Managing Hyperkalemia in Heart-Failure & CKD Patients

• Specialty Pharmacy Pipeline: A Glimpse at What’s Ahead

• Commercialization Considerations for Orphan/Rare, Cell & Gene, and Precision Medicine

• Cell, Gene and Beyond: What’s Working & Where Do We Go Next

• Cell & Gene Therapies Improve Outcomes and Even Cure Diseases — So Why Is Commercial Uptake Slow?

• GLP-1s: Riding the Wave of Innovative Medications

• Reimagining Specialty Drug Classification Parameters

• Rare-Disease Therapeutics in the Payer Landscape — Current State

• Neovascular Patient-Access session (“Elevating Patient Access and Care: Strategic Advantages of Specialized Pharmacy Networks Near COEs”)

• Beyond Limits: Rethinking Drug Distribution to Drive Patient-Centric Care

• Establishing an Optimal Specialty Network for Your Product ​

2. Market Access, Reimbursement & Policy

IRA, Medicare redesign, pricing reform, accreditation and regulatory headwinds.

• How the Next 90 Days May Shape the Future of Managed Medicare

• IRA Series Part III – 2025 Early Results: “The New Normal” for the Part D Benefit Redesign & MPPP

• IRA Implementation & the New Administration — Policy Considerations for Market-Access Strategy

• IRA Impact on Reimbursement, Access & Distribution of Part B Drugs (and Beyond)

• Navigating the IRA: What Have We Learned? What Is on the Horizon?

• Challenges in IRA Maximum Fair-Price Effectuation (Retrospective & Prospective Models)

• How the “Patient-as-Payer” Era Is Transforming Patient Access & Affordability

• Navigating the 340B Tug-of-War Between States & Manufacturers

• Navigating the Accreditation Maze: Uncovering Common Deficiencies & Solutions

• The First 100 Days: Key Insights on the New Administration & Congress

• US Pharmaceutical Trends, Issues & What’s Next?

• Beyond the Headlines: What Pharma Leaders Must Know About Tariffs, Supply Chains & Policy Changes

• Value / Outcome-Based Specialty Contracting — Where We Are, Where We’re Headed & the Endpoint

• The Capabilities Gap: How to Succeed in Market Access by Really Trying!

• Three Ways to Tell a Value Story Payers Want to Hear ​

3. Patient Access, Affordability & Health Equity

From social-determinant screening to financial assistance and the “patient voice.”

• Advancing Health Equity in Specialty Pharmacy Care

• The Business Imperative: Addressing Healthcare Inequities for Sustainable Growth

• Transforming Access & Affordability: The New Era of Pharmacy

• It Takes a Network: Tackling Affordability Together

• The State of Patient Access: Hurdles to Commercial Success in 2025 & Beyond

• The Cost of Care for Patients: Navigating the Financial Assistance Landscape

• Prescription for Change: Amplifying the Patient’s Voice in Specialty-Therapy Management

• Understanding the Product-Access Journey: Foundation of Innovative Support Programs

• Speaking Health & Human: Bridging the Gap to Quality Patient Care

• A Fresh Take on Patient Journeys — Project UnLonely: Healing Our Crisis of Disconnection

• Own the Narrative with AI in Patient Services

• Implementing a Pharmacist-Led Social-Determinants Screening & Intervention Program

• Personalizing the Specialty Patient Experience

• Women’s Health Luncheon: Unlocking a $90 B Market by 2030

• GLP-1s: Riding the Wave… (financial-coverage segment)

• Scooby-Doo & the Case of the Phantom Payer Switch (Benefit-Design Truths)

• Patient Access Journey session (Product-access foundation)

• Deal Rx: Preparing Your Company for Growth & Beyond (investor-readiness pairs patient outcomes with economics)

• Speaking Health & Human… (communication emphasis)

• Project UnLonely follow-up meet-up ​

4. Technology & Digital Transformation

AI, data science, automation and other tech reshaping pharmacy practice.

• AI and Its Impact on Healthcare & Pharmacy — An Introduction (Harry Travis presenting)

• Beyond AI: What Other Technologies Will Affect Pharmacy?

• Why AI Will Never Completely Automate Pharmacy: From Automation to Augmentation

• The Legal, Regulatory & Ethical Challenges Posed by Implementing Technology in Pharmacy Practice

• Own the Narrative with AI in Patient Services (cross-listed for patient-experience relevance) ​

5. Business Strategy, Operations & Distribution

Go-to-market models, supply-chain design, investor outlook and leadership issues.

• 2025: Entering a Brave New World

• Pharmacy Leadership Panel

• The Evolving Role of the Pharmacist

• Humanity in Action: The Importance of Empathy & Service

• Unique Approaches to Traditional Solutions: Lessons Learned from Building a New Pharmacy Benefit Model

• Best Practices in Free-Drug Program Management: Maximizing Manufacturer & Patient Outcomes

• Beyond Logistics: The Strategic Edge of Specialty Distributors

• Specialty Pharmacy Access in the Community

• Beyond Limits: Rethinking Drug Distribution to Drive Patient-Centric Care (cross-listed)

• Establishing an Optimal Specialty Network for Your Product (cross-listed)

• The Rise of Specialty in Gen Med… Are You Ready?

• Market & Patient Access: Anticipating the Chain Reaction

• Navigating the IDN Landscape: Key Insights to Inform Market-Access Strategy

• Collaboration in Action: Uniting Payers, Manufacturers, and IDNs

• Specialty Pharmacy’s Next Frontier: Where Investors See Opportunity ​

How to Use This Map

• Program-planning: quickly identify which blocks to attend if you focus on, say, IRA implementation or next-generation cell & gene therapies.

• BD / Networking: target sessions within “Business Strategy” for the highest concentration of C-suite and investor speakers.

• CE credit: all nine CE programs on the list fall into the Advanced-Therapies theme — a convenient way to collect required credits while staying on current science.

*MASLD = Metabolic dysfunction-associated steatohepatitis (new nomenclature replacing NASH).